Month Two · September 30, 2026
Enduring Internet Activities
1.75 CME / CE Credits
From Cholesterol to Dyslipidemia
Risk Assessment Reimagined
September 30, 2026 – March 30, 2027
This month
1.75 credits
Across two activities
Claim credit by April 30, 2027
Two Activities This Month
Choose where to start
Webinar
1.25 CME / CE Credits
Risk Assessment in 2026: PREVENT, ApoB, Lp(a), and CAC
Explore the PREVENT risk model, when to measure ApoB and Lp(a), appropriate use of coronary artery calcium (CAC) scoring, and risk enhancers that guide therapy decisions.
Christie Ballantyne
MD, MNLA
Seamus Whelton
MD
Podcast
0.5 CME / CE Credit
Beyond LDL: The Biomarkers That Matter
A companion discussion of risk assessment under the 2026 guideline, including PREVENT, ApoB, Lp(a), CAC scoring, and risk enhancers.
Jessica Peña
MD, FNLA
Ann Marie Navar
MD, PhD
Educational Objectives
What you’ll be able to do
Upon successful completion of the activities in Month Two, participants should be better able to:
1
Review the new PREVENT risk model.
2
Identify when to measure ApoB and Lp(a).
3
Apply coronary artery calcium (CAC) scoring appropriately.
4
Use risk enhancers to guide therapy decisions.
Faculty
Month Two Faculty
Webinar Faculty
Christie Ballantyne
MD, MNLA
Webinar Faculty
Seamus Whelton
MD
Podcast Faculty
Jessica Peña
MD, FNLA
Podcast Faculty
Ann Marie Navar
MD, PhD
Accreditation & Disclosures
Activity front matter
Each activity is separately accredited. The sections below apply to both the webinar and the podcast; credit designation and disclosures are listed separately for each.
Program Overview & Target Audience
Given the breadth and complexity of the 2026 dyslipidemia guidelines, and the well-documented gaps in risk stratification, primary prevention practice, treatment goal attainment, non-statin utilization, and population-specific management, there is a clear and urgent need for education that facilitates translation into clinical practice. Clinicians must not only understand the updated recommendations but also develop the competence and confidence to apply them across diverse patient populations and care settings.
By aligning educational content with documented practice gaps and delivering it in a format that supports sustained engagement, the program aims to improve clinician performance and ultimately enhance patient outcomes. Increased adoption of guideline-recommended practices has the potential to improve lipid control, reduce ASCVD events, and address persistent disparities in cardiovascular care.
Target Audience
This activity was designed for clinicians involved in ASCVD risk assessment and lipid management (physicians, pharmacists, advanced practice providers in primary care, dietitians, cardiology, endocrinology, and internal medicine).
Type of Activity
Enduring Internet Activity
Criteria for Success & Commercial Support
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at lipid.org/cme. The deadline to claim credit is April 30, 2027. Questions related to this content should be sent to cme@lipid.org.
Commercial Support
This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation, Merck & Co., Inc., and Amgen Inc.
Webinar — Credit Designation & Disclosures 1.25 Credits
CME/CE credit provided by the National Lipid Association
In support of improving patient care, The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designation Statement
The National Lipid Association designates this live internet activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
Pharmacist Accreditation Statement
Universal Activity Number UAN JA0007192-0000-26-033-H01-P (Knowledge)
This Activity has been approved for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education
Nursing Accreditation Statement
The maximum number of hours awarded for this CE activity is 1.25 contact hours.
Dietitians
Completion of this activity awards 1.25 continuing professional education units (CPEUs) for Registered Dietitians (RD) and Dietetic Technicians (DTR). RDs and DTRs should select activity type 102 in their Activity Logs.
Disclosure Information — Faculty, Planners & Reviewers
| Dave L. Dixon, PharmD, FNLA, CLS | Consultant – Innovation Horizons |
| Kaye-Eileen Willard, MD, FNLA | Has nothing to disclose. |
| Christie Ballantyne, MD, MNLA | Consultant – Abbott Diagnostics, Amgen, Arrowhead, AstraZeneca, Deka Seiken, Esperion, Genentech, Heartflow, Ionis, Lilly, New Amsterdam, Novo Nordisk, Roche Diagnostic Advisory Board – AstraZeneca, Merck, Novartis |
| Seamus Whelton, MD | Consultant – CVS Caremark, Philips |
| Susan Halli Demeter, DNP | Has nothing to disclose. |
| NLA Staff | Has nothing to disclose. |
Podcast — Credit Designation & Disclosures 0.5 Credit
CME/CE credit provided by the National Lipid Association
In support of improving patient care, The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Credit Designation Statement
The National Lipid Association designates this live internet activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
Pharmacist Accreditation Statement
Universal Activity Number UAN JA0007192-0000-26-034-H01-P (Knowledge)
This Activity has been approved for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education
Nursing Accreditation Statement
The maximum number of hours awarded for this CE activity is 0.5 contact hours.
Dietitians
Completion of this activity awards 0.5 continuing professional education units (CPEUs) for Registered Dietitians (RD) and Dietetic Technicians (DTR). RDs and DTRs should select activity type 102 in their Activity Logs.
Disclosure Information — Faculty, Planners & Reviewers
| Dave L. Dixon, PharmD, FNLA, CLS | Consultant – Innovation Horizons |
| Kaye-Eileen Willard, MD, FNLA | Has nothing to disclose. |
| Jessica Peña, MD, FNLA | Advisory Board – Novo Nordisk, Novartis Speaker – Novo Nordisk, NACE CME Independent Contractor – Turning Point HealthCare |
| Ann Marie Navar, MD, PhD | Consultant – Arrowhead, Eli Lilly, Merck, Amgen, New Amsterdam, Novartis, Genentech, Novo Nordisk Researcher – Heartflow, Amgen, Arrowhead |
| NLA Staff | Has nothing to disclose. |
Disclaimers, Unlabeled Use & Permissions
Disclosure of Unlabeled Use and Investigational Products
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclosure Declaration
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.
Permissions
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.
next up: Treatment Strategies and Targets
Month Three releases October 31, 2026 — Lipid targets and treatment intensification. Complete Month Two while it is open through April 30, 2027.